Great conversations at the @statnews STAT Summit in Boston last week, where $IMRX CEO @BenZeskind joined leaders from biotech, pharma, academia and policy on the issues shaping the future of medicine. #Biotech

Thank you to @Piper_Sandler for hosting $IMRX CEO @BenZeskind for a fireside chat at the Virtual Oncology Symposium, and for the opportunity to discuss our Deep Cyclic Inhibition approach. #Biotech

In a new @OncLive On Air podcast, Vincent Chung, MD, of @cityofhope discusses $IMRX’s atebimetinib and its development in metastatic #PancreaticCancer. Listen: buff.ly/EXiNWz2

Proud to see our research featured on the cover of @CR_AACR! The study highlights atebimetinib's broad antitumor activity in RAS-mutant cancer models and the science driving our work to advance new treatment approaches for pancreatic cancer. buff.ly/D6GQD99

Can we change the outlook for people facing pancreatic cancer? Dr. Meredith Pelster of @SarahCannonDocs discusses the Phase 3 #MAPKeeper301 trial evaluating atebimetinib + chemo in 1L pancreatic cancer in a new @OncLive interview. Watch: buff.ly/UnbI9bg

Pancreatic cancer treatment is evolving—new therapies are in development and clinical trials are creating more options than ever. Participation helps advance science and may open access to cutting-edge care. Learn more: buff.ly/70gObA0

We’re hiring! Join $IMRX as Associate Director, Formulation Development and help advance innovative oncology programs from candidate nomination through clinical development. Bring your expertise to our mission to transform cancer care. Apply here: buff.ly/UuFvOFv

Great conversations at 2026 @AACR Conference on Pancreatic Cancer! We loved seeing the interest in our poster & hearing thoughtful questions about new data on atebimetinib’s potential dual mechanism: reducing tumor volume while preserving body mass. Thanks to all who stopped by!

Thank you to @LetsWinPC for highlighting atebimetinib and the science behind our deep cyclic MEK inhibition approach, now being evaluated in Phase 3 MAPKeeper 301. Read more: buff.ly/btbGri3

$IMRX is heading to #SITC2026! New preclinical data to be presented demonstrated atebimetinib’s ability to enhance PD-1 checkpoint blockade in RAS-mutant tumor models. We look forward to sharing these findings w/ the immuno-oncology community. $IMRX buff.ly/PE24Ynf

Honored to support and present at the @PanCAN Scientific Summit 2026, where researchers, clinicians, patient advocates and industry came together around a shared goal: accelerating meaningful advances for people living with pancreatic cancer. #PanCAN #PancreaticCancer

Today, $IMRX announced new data presented at the 2026 AACR Conference on Pancreatic Cancer supporting a potential dual mechanism through which atebimetinib may improve survival in pancreatic cancer: reducing tumor volume while preserving body mass. buff.ly/OHBZ2ms

Today is cancer cachexia awareness day. Raising awareness for the wasting syndrome that touches up to 80% of people with advanced cancer. Learn more about cancer cachexia here: buff.ly/JqRdEZc #CancerCachexiaAwarenessDay #CCAD

Today $IMRX announced that a trial-in-progress abstract featuring the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP has been accepted for poster presentation at @myESMO 2026, Oct. 23-27 in Madrid, Spain. More details: buff.ly/k0qj5ju

At the H.C. Wainwright 28th Annual Global Investment Conference last week, we shared updates on atebimetinib and our Phase 3 MAPKeeper 301 study and engaged with investors in 1x1 meetings.

Great connecting with leaders across the RAS community at the 8th RAS-Targeted Drug Development Summit in Boston, where we presented our work advancing atebimetinib. Encouraged by the progress across the field and the opportunity ahead for patients with RAS-driven cancers.

At the @cantorfitzgerld Global Healthcare Conference, we shared updates on atebimetinib and our Phase 3 MAPKeeper 301 study, and engaged with investors in 1x1 meetings. Strong interest reinforced the opportunity ahead in first-line metastatic pancreatic cancer. #PancreaticCancer

A new @OncLive article highlights MAPKeeper 301, our Phase 3 study evaluating investigational atebimetinib + chemo in 1L pancreatic cancer. Learn more at buff.ly/XCk2khB and read the article buff.ly/WN8o2Kr #PancreaticCancer #ClinicalTrials

Please join us on Monday at noon ET live or via webcast for a fireside chat at the HC Wainwright 28th Annual Global Investment Conference. Access the webcast here: ir.immuneering.com/news-even…

At the @AACR Conference on Pancreatic Cancer, Peter Vu, M.D., MHA, of @UCSDHealth will present data on atebimetinib’s ability to reduce tumor volume while preserving body mass. Find us at Poster #A134, Sat., Sept. 26 between 6 - 8pm PT. Learn more: ir.immuneering.com/news-rele…